All systemic allergic reactions have the potential of progressing to anaphylaxis and becoming life-threatening. Epinephrine needs to be given as soon as symptoms occur because it is the only medication proven to stop a potentially life-threatening allergic reaction. Delay or failure to use epinephrine greatly increases the chance of hospitalization and has been associated with fatalities.
ARS is developing a needle-free, low-dose intranasal epinephrine nasal spray for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis. Intended for use at the first signs of an allergic response, a needle-free nasal spray may allow for improved patient and caregiver preparedness and response, to give epinephrine quickly, confidently, and without hesitation that is caused by fear of needles.
It is our commitment to provide patients and their families with a new option to rapidly resolve symptoms and prevent progression to severe anaphylaxis.